Shares in Netherlands biotech Kiadis rose sharply on the news that it would start developing a natural killer (NK) cell therapy for COVID-19, but later lost most of the gains o
After decades of clinical research targeting development of more “personalised” medicines, the biotechnology sector is now starting to deliver with the first generation of promising new cel
